Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

Go back to Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
(NASDAQ: PHVS) Delayed: 38.00 +0.45 (1.20%)
Previous Close $37.55    52 Week High
Open $37.81    52 Week Low
Day High $38.93    P/E N/A 
Day Low $37.60    EPS
Volume 1,137,444